biosimilar portfolio

Celltrion Inc., South Korea’s largest biosimilar developer, will issue bonus shares to bolster its stock performance, which has been in the do...

Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...

The Korea Investment Corporation (KIC) is zeroing in on Asia’s real estate market by region, while targeting residential facilities and data c...

The National Pension Service (NPS), the world’s third-largest pension fund, has been further diversifying its portfolio through increased expo...

Greystar Real Estate Partners, the largest housing investment firm in the US, has hired Kang Junghwan, former managing director and head of portfoli...

South Korea’s second-largest conglomerate SK Group is seeking to divest SK Signet Inc., four years after acquiring the EV charger manufacturin...

Harman International Industries Inc., wholly owned by Samsung Electronics Co., has acquired Masimo Corp.’s audio business for $350 million, a ...

South Korea’s pharmaceutical exports are on course to surpass $10 billion this year, underscoring the country’s growing clout in the glo...

South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Digital assets are poised for robust structural growth – not just as investment vehicles but as strategic assets – fueled by growing ins...

South Korea’s National Pension Service (NPS) is projected to nearly double its fund size to 3,500 trillion won ($2.38 trillion) by 2050, follo...

LG Energy Solution Ltd., the world’s third-largest battery maker, and Doosan Bobcat Inc., a global construction machinery producer, said on We...

The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, plans to intr...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...

LX International Corp., the trading unit of South Korea’s LX Group, said on Friday it is seeking to acquire a nickel mine and a copper mine in...

South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...

SK Group on Thursday promoted the keymen of its business overhauls to top posts at intermediary holding company SK Discovery Co. and battery maker S...

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...